Go-ahead for trials of electric drug delivery:
This article was originally published in Clinica
Trials of a device which uses electric fields to open pores in cells to deliver cancer drugs are to begin in Canada. The Phase II study will assess Genetronics Biomedical's MedPulser device as a way of delivering the drug Bleomycin in the treatment of advance head and neck tumours. Some 25 patients will be studied at four sites throughout Canada. Phase II trials have already begun in the US and the company said the preliminary data show that very low doses of the drug are effective.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.